<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328587</url>
  </required_header>
  <id_info>
    <org_study_id>110134</org_study_id>
    <secondary_id>11-H-0134</secondary_id>
    <nct_id>NCT01328587</nct_id>
  </id_info>
  <brief_title>Eltrombopag for Moderate Aplastic Anemia</brief_title>
  <official_title>A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  Moderate aplastic anemia is a blood disease which may require frequent blood and&#xD;
           platelet transfusions. Sometimes patients with this disease can be treated with&#xD;
           immunosuppressive drugs. Not all patients respond and not all patients are suitable for&#xD;
           this treatment.&#xD;
&#xD;
        -  Thrombopoietin (TPO) is a protein made by the body. The bone marrow needs TPO to produce&#xD;
           platelets. TPO may also be able to stimulate bone marrow stem cells to produce red cells&#xD;
           and white cells. However, TPO cannot be given by mouth. This has led researchers to&#xD;
           develop the drug eltrombopag, which acts in the same way and can be given by mouth.&#xD;
           Eltrombopag has been shown to safely increase platelet numbers in healthy volunteers and&#xD;
           in patients with other chronic blood diseases, including severe aplastic anemia.&#xD;
           Researchers are interested in looking at whether eltrombopag can be given to people with&#xD;
           moderate aplastic anemia and significantly low blood cell counts.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To evaluate the safety and effectiveness of eltrombopag in people with moderate aplastic&#xD;
      anemia or patients with bone marrow failure and unilineage cytopenia who need treatment for&#xD;
      significantly low blood cell counts.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - People at least 2 years of age who have moderate aplastic anemia or bone marrow failure and&#xD;
      unilineage cytopenia,and significantly low blood cell counts.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Patients will be screened with a physical examination, medical history, blood tests, a&#xD;
           bone marrow biopsy, and an eye exam.&#xD;
&#xD;
        -  Patients will receive eltrombopag by mouth once a day.&#xD;
&#xD;
        -  Patients will have weekly blood tests to monitor the effectiveness of the treatment and&#xD;
           adjust the dose in response to possible side effects.&#xD;
&#xD;
        -  Patients may continue to take eltrombopag if their platelet count or hemoglobin&#xD;
           increases, their requirement for platelet or blood transfusion decreases after 16 to 20&#xD;
           weeks of treatment, and there have been no serious side effects. Access to the drug will&#xD;
           continue until the study is closed. Patients will be asked to return for a follow-up&#xD;
           visit 6 months after the last dose of medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Moderate aplastic anemia (MAA) is a blood disease which can be effectively treated with&#xD;
      immunosuppressive drug regimens. However, a significant number of patients have persistent&#xD;
      cytopenias. Currently, the treatment of these patients is regular transfusion, which are&#xD;
      expensive, inconvenient, and associated with serious side effects related to iron overload,&#xD;
      or cytokines such as erythropoietin or G-CSF, which are expensive, and not effective in many&#xD;
      patients.&#xD;
&#xD;
      Thrombopoietin (TPO) is a protein made by the body that is important for normal production of&#xD;
      platelets by the bone marrow. TPO may also be able to stimulate bone marrow stem cells to&#xD;
      produce red cells and white cells. TPO cannot be given by mouth, and as an alternative, a&#xD;
      drug, eltrombopag, has been designed that acts in the same way as TPO but is stable and&#xD;
      active when given by mouth. Eltrombopag has been shown to safely increase platelet numbers in&#xD;
      healthy volunteers and in patients with chronic immune thrombocytopenic purpura (ITP). It has&#xD;
      been recently granted accelerated approval by FDA on November 20, 2008 for the treatment of&#xD;
      patients with chronic immune thrombocytopenic purpura (ITP) who have had an insufficient&#xD;
      response to standard therapies.&#xD;
&#xD;
      We have previously shown encouraging results when eltrombopag is used to treat patients with&#xD;
      severe aplastic anemia, with some patients responding with increases in platelets, red cells&#xD;
      and white cells. Given these encouraging early preliminary results in our clinical trial&#xD;
      using eltrombopag in Severe Aplastic Anemia (SAA), and low toxicity and ease of&#xD;
      administration of this drug, we now propose a non-randomized pilot phase II study of&#xD;
      eltrombopag in moderate aplastic anemia patients with clinically significant thrombocytopenia&#xD;
      or anemia. Patients with MAA may not reach criteria for SAA, but none the less may be&#xD;
      transfusion-dependent or have significant symptoms from cytopenias. We hypothesize that&#xD;
      patients with MAA as compared to SAA may have a better chance of response, due to better&#xD;
      residual marrow function in MAA patients compared to SAA.&#xD;
&#xD;
      Eligible patients can have treated or untreated MAA, as well as counts meeting criteria for&#xD;
      MAA following a partial response to treatment with immunosuppression for SAA. We will also&#xD;
      include patients with bone marrow failure and unilineage cytopenia. Treatment response for&#xD;
      the platelet lineage is defined as platelet count increases to 20,000/microL above baseline&#xD;
      at 16 to 20 weeks, or freedom from platelet transfusions for greater than or equal to 8 weeks&#xD;
      in transfusion-dependent patients. For patients with anemia (untransfused hemoglobin less&#xD;
      than or equal to 8.5 g/dL), a treatment response will be an increase in Hb by greater than or&#xD;
      equal to 1.5g/dl at four months, measured on at least 2 serial measurements and sustained for&#xD;
      1 month or more without transfusion support OR for transfusion dependent patients, reduction&#xD;
      of units of RCC transfused by 50 percent/8 weeks compared with the pretreatment transfusion&#xD;
      number in the previous 8 weeks or transfusion independence (no transfusions for greater than&#xD;
      or equal to 8 weeks). Subjects with evidence for a clinical response in any lineage at 16&#xD;
      weeks but not yet meeting full primary endpoint response criteria, and who are tolerating&#xD;
      investigational treatment, may receive an additional 4 weeks of eltrombopag and be reassessed&#xD;
      after 20 weeks. At that time, if they meet primary endpoint response criteria, they will be&#xD;
      eligible to enter the extended access part of the study. If they do not meet primary endpoint&#xD;
      response criteria, eltrombopag will be discontinued.&#xD;
&#xD;
      The primary objective is to assess the safety and efficacy of the oral thrombopoietin&#xD;
      receptor agonist (TPO-R agonist) eltrombopag in moderate aplastic anemia patients or patients&#xD;
      with bone marrow failure and unilineage cytopenia. Secondary objectives include the analysis&#xD;
      of the incidence and severity of bleeding, clonal evolution to PNH, clonal chromosomal&#xD;
      population in bone marrow, myelodysplasia by morphology, or acute leukemia and the impact on&#xD;
      quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 1, 2011</start_date>
  <completion_date type="Anticipated">March 30, 2025</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Drug Responders</measure>
    <time_frame>16-20 weeks from start of drug</time_frame>
    <description>The portion of drug responders as defined by changes in the platelet count and/or platelet transfusion requirements or hemoglobin and/or PRBC transfusion requirements and the toxicity profile as measured using the CTCAE criteria. Treatment response for the platelet lineage is defined as an absolute increase of ≥20x10^9/L above baseline at 16 or 20 weeks, measured on at least two serial measurements performed one week apart and sustained for 1 month or more without support of platelet transfusions, or for transfusion dependent patients stable platelet counts with transfusion independence for ≥ 8 weeks. For patients with anemia (untransfused hemoglobin ≤ 8.5 g/dL), a treatment response will be an increase in Hb by ≥1.5g/dL at four months, measured on at least 2 serial measurements and sustained for 1 month or more without transfusion support OR for transfusion dependent patients, reduction of units of RCC transfused by 50%/8 weeks compared with the pretreatment transfusion number in th</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Moderate Aplastic Anemia</condition>
  <condition>Unilineage Bone Marrow Failure Disorders</condition>
  <arm_group>
    <arm_group_label>Eltrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 50mg/day (East Asian ancestry 25mg/day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.</description>
    <arm_group_label>Eltrombopag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Current diagnosis of moderate aplastic anemia or unilineage bone marrow failure disorders.&#xD;
&#xD;
          -  Moderate aplastic anemia is defined as aplastic anemia (hypocellular bone marrow for&#xD;
             age) with no evidence for other disease processes causing marrow failure, and&#xD;
             depression of at least two out of three blood counts below the normal values:&#xD;
&#xD;
               -  ANC less than or equal to 1200/mm(3)&#xD;
&#xD;
               -  platelet count less than or equal to 70,000/mm(3)&#xD;
&#xD;
               -  anemia with hemoglobin less than or equal to 8.5 g/dL and absolute reticulocyte&#xD;
                  count less than or equal to 60,000/mm(3) in transfusion-dependent patients but&#xD;
                  not fulfilling the criteria for severe disease defined by depression of two of&#xD;
                  the three peripheral counts:&#xD;
&#xD;
               -  ANC less than or equal to 500/mm(3)&#xD;
&#xD;
               -  platelet count less than or equal to 20,000/mm(3)&#xD;
&#xD;
          -  reticulocyte count less than or equal to 60,000/mm(3)&#xD;
&#xD;
          -  Unilineage bone marrow failure disorders are defined:&#xD;
&#xD;
               -  Hemoglobin less than 8.5 g/dL and reticulocyte count less than 60,000 or red cell&#xD;
                  transfusion dependent and hypocellular to normocellular bone marrow for age with&#xD;
                  significantly reduced erythroid precursors.&#xD;
&#xD;
               -  OR thrombocytopenia less than or equal to 30,000/uL or platelet transfusion&#xD;
                  dependent and hypocellular to normocellular bone marrow for age with reduced&#xD;
                  megakaryocytes.&#xD;
&#xD;
          -  No evidence of viral or drug suppression of the marrow, dysplasia, or underproduction&#xD;
             anemias secondary to B12, folate, iron or other reversible causes.&#xD;
&#xD;
        Platelet transfusion dependent is defined as the need for platelet transfusion due to&#xD;
        platelet counts of &lt; 10,000/microL with no bleeding (prophylactic transfusion) or &lt;&#xD;
        20,000/microL with bleeding (therapeutic transfusion). Red cell transfusion dependent is&#xD;
        defined as transfusion of greater than 4 units of blood in the 8 weeks prior to study&#xD;
        entry.&#xD;
&#xD;
        Age greater than or equal to 2 years old&#xD;
&#xD;
        Weight greater than 12 kg&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Known diagnosis of Fanconi anemia&#xD;
&#xD;
        Counts that meet criteria for severe aplastic anemia&#xD;
&#xD;
        Infection not adequately responding to appropriate therapy&#xD;
&#xD;
        HIV positivity&#xD;
&#xD;
        Creatinine &gt; 2.5 mg/dL&#xD;
&#xD;
        Bilirubin &gt; 2.0 mg/dL, including congenital abnormalities in the bilirubin count&#xD;
&#xD;
        SGOT or SGPT &gt;5 times the upper limit of normal&#xD;
&#xD;
        Hypersensitivity to eltrombopag or its components&#xD;
&#xD;
        Female subjects who are nursing or pregnant or are unwilling to take oral contraceptives or&#xD;
        refrain from pregnancy if of childbearing potential&#xD;
&#xD;
        Evidence of an active malignant hematological or clonal disorder, or abnormal cytogenetic&#xD;
        studies of the bone marrow performed within 12 weeks of study entry.&#xD;
&#xD;
        Unable to understand the investigational nature of the study or give informed consent or&#xD;
        does not have a legally authorized representative or surrogate that can provide informed&#xD;
        consent&#xD;
&#xD;
        Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious,&#xD;
        or metabolic disease of such severity that it would preclude the patient's ability to&#xD;
        tolerate protocol therapy, or that death within 7-10 days is likely.&#xD;
&#xD;
        Treatment with horse or rabbit ATG or Campath within 6 months of study entry.&#xD;
&#xD;
        Treatment with cytokines such as G-CSF or Erythropoietin.&#xD;
&#xD;
        Subjects with known cirrhosis in severity that would preclude tolerability of eltrombopag&#xD;
        as evidenced by albumin less than 35g/L.&#xD;
&#xD;
        Life expectancy of less than 3 months&#xD;
&#xD;
        Patients with an active diagnosis of cancer who have received chemotherapeutic treatment or&#xD;
        other specific antineoplastic drugs or radiation therapy within 6 months of study entry.&#xD;
&#xD;
        Unable to take investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia E Dunbar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-H-0134.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995 Jun 15;85(12):3367-77. Review.</citation>
    <PMID>7780125</PMID>
  </reference>
  <reference>
    <citation>Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006 Oct 15;108(8):2509-19. Epub 2006 Jun 15. Review.</citation>
    <PMID>16778145</PMID>
  </reference>
  <reference>
    <citation>Zeng W, Maciejewski JP, Chen G, Risitano AM, Kirby M, Kajigaya S, Young NS. Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. Br J Haematol. 2002 Dec;119(3):803-9.</citation>
    <PMID>12437663</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <results_first_submitted>March 29, 2019</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmunity</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Cytokine</keyword>
  <keyword>Hematopoiesis</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Aplastic Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01328587/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eltrombopag</title>
          <description>Patients will receive Eltrombopag ( thrombopoietin receptor agonist) by mouth once a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eltrombopag</title>
          <description>Patients will receive Eltrombopag ( thrombopoietin receptor agonist) by mouth once a day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Drug Responders</title>
        <description>The portion of drug responders as defined by changes in the platelet count and/or platelet transfusion requirements or hemoglobin and/or PRBC transfusion requirements and the toxicity profile as measured using the CTCAE criteria. Treatment response for the platelet lineage is defined as an absolute increase of ≥20x10^9/L above baseline at 16 or 20 weeks, measured on at least two serial measurements performed one week apart and sustained for 1 month or more without support of platelet transfusions, or for transfusion dependent patients stable platelet counts with transfusion independence for ≥ 8 weeks. For patients with anemia (untransfused hemoglobin ≤ 8.5 g/dL), a treatment response will be an increase in Hb by ≥1.5g/dL at four months, measured on at least 2 serial measurements and sustained for 1 month or more without transfusion support OR for transfusion dependent patients, reduction of units of RCC transfused by 50%/8 weeks compared with the pretreatment transfusion number in th</description>
        <time_frame>16-20 weeks from start of drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag</title>
            <description>Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 50mg/day (East Asian ancestry 25mg/day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.&#xD;
Eltrombopag: Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Drug Responders</title>
          <description>The portion of drug responders as defined by changes in the platelet count and/or platelet transfusion requirements or hemoglobin and/or PRBC transfusion requirements and the toxicity profile as measured using the CTCAE criteria. Treatment response for the platelet lineage is defined as an absolute increase of ≥20x10^9/L above baseline at 16 or 20 weeks, measured on at least two serial measurements performed one week apart and sustained for 1 month or more without support of platelet transfusions, or for transfusion dependent patients stable platelet counts with transfusion independence for ≥ 8 weeks. For patients with anemia (untransfused hemoglobin ≤ 8.5 g/dL), a treatment response will be an increase in Hb by ≥1.5g/dL at four months, measured on at least 2 serial measurements and sustained for 1 month or more without transfusion support OR for transfusion dependent patients, reduction of units of RCC transfused by 50%/8 weeks compared with the pretreatment transfusion number in th</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>42 months from enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eltrombopag</title>
          <description>Patients will receive Eltrombopag ( thrombopoietin receptor agonist) by mouth once a day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic Ovarian CA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>blood and lymphatic system d/s other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gingival Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>spleen disorder/splenic varices</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>spleen disorder/splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>BLE edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>dyspnea on exertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>fatigue/angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>scrotal edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>External Ear pain/discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>otitis media/external ear inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Burning Eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>eye tingling/pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood in stool</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>collagenous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>diarrhea/stomach cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>epigastric tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>foodpoisoning/gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>GI illness(nausea, vmitting, diarrhea)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gi symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Gum Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>h pylori</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>intermittent lower pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Loose Stool</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Mild constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>nausea/diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>nausea/vomiting/abd cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pinworms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>rectal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Viral Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Worsening GERD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>facial edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>intermittent night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>LE edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>lightheaded</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>CTLA 4 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscessed Tooth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>C diff</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>strep throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>tooth #30 infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>UTI/Inflammed prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>yeast infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>easy bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Foot pain from fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>shoulder pain from fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>AST increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Elevated Liver Enzymes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>yellowing skin/eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>R Breast Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>R Calf Cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rib pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizzy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>fingers tingly&amp;#39;-peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>headaches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dark urine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest cold</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cold Sxs</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>dry cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspnea on Exertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Mild Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>sinus pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>sleep apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Viral URI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>facial rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>left post auricular skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash on Arm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dunbar, Cynthia</name_or_title>
      <organization>National Heart Lung and Blood Institute</organization>
      <phone>+1 301 827 1164</phone>
      <email>dunbarc@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

